My Grandmother Forgot My Name
It happened on a Tuesday in September. She looked at me the way you look at someone you think you recognize from somewhere but can't quite place. I was twenty-six. She'd known me my entire life. The diagnosis had come eighteen months earlier, but that Tuesday was when I understood what Alzheimer's actually is. Not a memory problem. A person-erasure problem.
So when I see headlines about progress in early detection — actual, measurable progress — I pay attention. Not as a policy observer. As a granddaughter who would have done anything to have had more time.
The advances in amyloid PET scanning and blood-based biomarker testing over the past three years are genuinely significant. Researchers at several major academic medical centers have demonstrated that amyloid plaques — the protein buildups associated with Alzheimer's progression — can now be detected in blood samples up to fifteen years before cognitive symptoms appear. Fifteen years. That's not a footnote. That's a revolution in what's possible.
Where the Government Has Failed
Here's the part that makes me angry. The National Institutes of Health spent decades dramatically underfunding Alzheimer's research relative to the scale of the disease. In 2015, federal funding for Alzheimer's research was under $600 million annually, despite the disease affecting more than five million Americans and costing the healthcare system over $200 billion per year. Cancer research received more than five times that amount.
The gap has narrowed since then — Congress has increased Alzheimer's funding substantially, to over $3.7 billion annually as of the last appropriations cycle. But the political incentives around medical research funding are distorted in ways that hurt diseases like Alzheimer's. Research timelines for neurological diseases are long. Political timelines are short. There's no ribbon campaign as culturally entrenched as the pink ribbon. The disease primarily affects the elderly, a population that doesn't march or generate viral moments.
What it does is quietly devastate families. Millions of them. Mostly invisible to the political class until someone schedules a webinar.
What Early Detection Actually Changes
The promise of early detection isn't just earlier treatment. It's the possibility of prevention. If you can identify the biological markers fifteen years out, you have a window to intervene — with lifestyle modifications, with pharmaceutical trials, with whatever therapeutics the research pipeline produces in the years ahead. That window closes the moment symptoms appear.
Which means every year of delay in making these detection tools widely available — in getting them covered by insurance, in training primary care physicians to order and interpret them, in building the clinical infrastructure to act on early-stage findings — is a year of preventable disease. A year of preventable loss.
The federal government's job here isn't complicated. Fund the research. Accelerate the FDA approval pathway for diagnostics with strong evidence behind them. Work with CMS to ensure Medicare coverage for early detection screenings for high-risk patients. None of this requires inventing new bureaucracy. It requires the existing bureaucracy to function with urgency instead of inertia.
What it doesn't require is a livestreamed panel discussion on a congressional website. I'm not opposed to awareness. I'm opposed to awareness as a substitute for action. My grandmother didn't need more awareness. She needed a blood test that existed twenty years before the science caught up to the need.
The science is catching up. The question is whether the political will is following. Based on the current pace of implementation, I'm not optimistic. But I'm watching. And so are a lot of families who know exactly what it looks like when the window closes.
